06/23/22 4:20 PMNasdaq : VTGN earningsVistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate UpdateVistaGen Therapeutics, Inc., a late clinical-stage, central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a corporate update.RHEA-AIneutral
06/22/22 8:30 AMNasdaq : VTGN clinical trialVistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety DisorderVistaGen Therapeutics, Inc., a late clinical-stage central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that the last patient has completed the study protocol in its PALISADE-1 Phase 3 clinical trial of PH94B for the...RHEA-AIvery positive
06/17/22 8:30 AMNasdaq : VTGN conferencesearningsVistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022VistaGen Therapeutics, Inc. a late clinical-stage, central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a conference call and webcast on Thursday, June 23, 2022, at 2:00 p.m. Pacific Time to report its...RHEA-AIneutral
06/02/22 8:30 AMNasdaq : VTGN conferencesclinical trialVistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual MeetingVistaGen Therapeutics, Inc., a late clinical-stage, central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that the clinical trial abstract for its exploratory Phase 2 A clinical study in adjustment disorder with...RHEA-AIneutral
05/27/22 8:30 AMNasdaq : VTGN conferencesVistaGen to Participate in Upcoming June Investor ConferencesVistaGen Therapeutics, Inc., a late clinical-stage, central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in the following upcoming investor conferences in...RHEA-AIneutral
05/05/22 8:30 AMNasdaq : VTGN VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety DisorderVistaGen Therapeutics, Inc., a late clinical-stage, central nervous system focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a key regulatory update on its PALISADE Phase 3 Program for PH94B for the acute treatment of anxiety in adults...RHEA-AInegative
05/02/22 8:00 AMNasdaq : VTGN managementVistaGen Appoints Reid Adler as Chief Legal OfficerVistaGen Therapeutics, Inc. a late clinical-stage, central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer. “It's a privilege to join the VistaGen leadership team...RHEA-AIneutral
04/21/22 8:00 AMNasdaq : VTGN conferencesclinical trialVistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific CongressesVistaGen Therapeutics, Inc. a late clinical-stage, central nervous system focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that researchers will present preclinical data supporting the differentiated mechanism of action for VistaGen’ s...RHEA-AIneutral
04/12/22 7:00 AMNasdaq : VTGN clinical trialVistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94BVistaGen Therapeutics, Inc. and AffaMed Therapeutics today announced they have completed regulatory preparations to initiate PALISADE Global, a Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of VistaGen’ s PH94B for the acute treatment of anxiety in adults with social anxiety disorder, in the...RHEA-AIpositive
03/24/22 8:00 AMNasdaq : VTGN conferencesVistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth ConferenceVistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other centralRHEA-AIneutral